Journal of Diabetes Research最新文献

{"title":"Effects of Statin Therapy on Glycemic Control and Associated Factors Among Type 2 Diabetes Mellitus Patients in Northeastern Tanzania: A Retrospective Cohort Study.","authors":"Daniel P Mujuni, Kajiru G Kilonzo, Abid M Sadiq, Norman J Kyala, Philip C Makupa, Sweetness N Laizer, Elifuraha W Mkwizu, Furaha S Lyamuya, Elichilia R Shao, Erick A Mboya, Nyasatu G Chamba","doi":"10.1155/jdr/6626154","DOIUrl":"10.1155/jdr/6626154","url":null,"abstract":"<p><p><b>Introduction:</b> Statins have been implicated in poor glycemic control among patients with diabetes mellitus (DM), prompting the US Food and Drug Administration (FDA) to update warning labels on all statins to reflect the risk of increased blood glucose levels. However, few studies from sub-Saharan Africa have assessed this concern. This study investigated the effects of statins on glycemic control among patients with Type 2 diabetes mellitus (T2DM) in Kilimanjaro, northeastern Tanzania. <b>Materials and Methods:</b> This was a hospital-based retrospective cohort study evaluating changes in glycated hemoglobin (HbA_1c) at 1-3, 7-12, and 19-24 months, as the primary outcome, comparing statin users and nonusers among T2DM patients attending DM clinic at Kilimanjaro Christian Medical Centre in Tanzania. Binomial regression models were fitted to calculate adjusted risk ratios for independent predictors of a ≥ 0.2% rise in HbA_1c, with statistical significance set at <i>p</i> < 0.05. <b>Results:</b> Out of 122 patients, 51 (41.8%) were on statin therapy. Among these, 46 (90.2%) were prescribed atorvastatin. Statin users had an increase of mean HbA_1c from 10.6% ± 2.7% at baseline compared to 11.6% ± 2.8% at 1-3 months (<i>p</i> = 0.114), followed by a decrease to 10.1% ± 2.2% at 7-12 months (<i>p</i> = 1.0), and 10.0% ± 2.5% at 19-24 months (<i>p</i> = 1.0). However, atorvastatin users (<i>n</i> = 46) had a significant increase of mean HbA_1c from 10.7% ± 2.8% at baseline compared to 11.9% ± 2.7% at 1-3 months (<i>p</i> = 0.04). In contrast, nonstatin users had a consistent and significant decrease in HbA_1c from 11.3% ± 2.8% at baseline compared to 9.7% ± 2.2% at 1-3 months (<i>p</i> = 0.001), to 9.7% ± 2.6% at 7-12 months (<i>p</i> = 0.011), and to 9.3% ± 2.2% at 19-24 months (<i>p</i> = 0.001). <b>Conclusion:</b> Statin therapy among patients with T2DM was associated with short-lived worsening of glycemic control at 1-3 months posttherapy.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"6626154"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic Insights Into Qidan Yixin Decoction for Diabetic Cardiomyopathy via Macrophage Polarization.","authors":"Yi Liu, Juan Zhang, Wei Gao, Quancheng Han, Yitao Xue, Xiujuan Liu","doi":"10.1155/jdr/7578626","DOIUrl":"10.1155/jdr/7578626","url":null,"abstract":"<p><p><b>Background:</b> Diabetic cardiomyopathy (DCM) has a multifactorial etiology, and no specific treatment is available for its management. Qidan Yixin decoction (QDYXD) demonstrated encouraging clinical results in treating DCM; however, its underlying mechanics are yet unclear. <b>Methods:</b> Network pharmacology was applied to determine the active ingredients and targets of QDYXD. The GeneCards and GEO databases were used to retrieve genes associated with DCM and macrophage polarization. These targets were subjected to GO and KEGG enrichment analyses, immune infiltration study, and PPI network design. The core targets were further refined using SVM-RFE, LASSO, and random forest algorithms. Docking the core targets with the main active components followed. For experimental validation, rat models were created. <b>Results:</b> There were 48 potential targets in all. Quercetin, methyl palmitate, luteolin, and tanshinone IIA were identified as the primary active components. Enrichment analysis indicated that one of the key pathways associated with the potential targets was the signaling pathway of HIF-1. Machine learning techniques were used to identify two core targets, LDHA and PGK1. Animal experiments demonstrated that QDYXD can suppress the upregulation of PGK1, LDHA, and HIF1A; block the polarization of M1 macrophages; and considerably enhance DCM rats' cardiac function. <b>Conclusion:</b> QDYXD improves cardiac function in DCM by attenuating M1 macrophage polarization and inhibiting the HIF-1 signaling pathway, specifically through the modulation of PGK1, LDHA, and HIF1A. This study provides preliminary insights into how QDYXD modulates macrophage polarization during DCM treatment. Moreover, the identification of potential active components and core molecular targets of QDYXD offers promising directions for future drug development in DCM therapy.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"7578626"},"PeriodicalIF":3.4,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12331402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal Associations of Iron Status With the Renal Function and Diabetic Nephropathy in Patients With Diabetes Mellitus: A Two-Sample Mendelian Randomization Study.","authors":"Ying Zhang, Wujian Peng, Jianrong Huang, Wenchang Zhang, Peishan Jiang, Yuqin He, Meiyun Wang","doi":"10.1155/jdr/6658794","DOIUrl":"10.1155/jdr/6658794","url":null,"abstract":"<p><p>This study was to explore the causal effect of iron status on renal function and the risk of diabetic nephropathy in diabetic patients. The data on exposures including ferritin, serum iron, transferrin saturation (TSAT), and total iron-binding capacity (TIBC) were obtained from a genome-wide association study (GWAS). The outcomes were diabetic nephropathy, Type 1 diabetes mellitus (T1DM) with renal complications, Type 2 diabetes mellitus (T2DM) with renal complications, estimated glomerular filtration rate (creatinine) (eGFRcrea) in diabetes mellitus, and urinary albumin-to-creatinine ratio (UACR) in diabetes mellitus. The causal associations of exposures and outcomes were analyzed using MR analysis with the inverse variance-weighted (IVW) method as the primary analytical method. Leave-one-out analysis was utilized to find any individual SNP associated with exposures influencing outcomes. Odds ratio (OR) and 95% confidence interval (95% CI) were estimated. The <i>F</i> values of all the SNPs were > 10, indicating a sufficient strength of the instrumental variables. The results from pleiotropy analysis indicated that most SNPs showed no horizontal pleiotropy (<i>p</i> > 0.05). The ferritin level had a causal effect on decreased eGFRcrea level in diabetes mellitus patients (OR = 0.937, 95% CI: 0.887-0.990) and increased risk of T1DM with renal complications (OR = 1.783, 95% CI: 1.005-3.162). TIBC level was causally associated with decreased risk of diabetic nephropathy (OR = 0.864, 95% CI: 0.771-0.968) and T1DM with renal complications (OR = 0.743, 95% CI: 0.603-0.916). Ferritin level had a causal effect on eGFRcrea level in diabetes mellitus patients and T1DM with renal complications. In conclusion, TIBC levels are causally linked to a lower risk of both diabetic nephropathy and T1DM with renal complications. The findings might provide a reference for using TIBC levels as a biomarker for prevention and treatment of diabetic nephropathy in the future. As the study was an MR analysis based on gene, the value of TIBC levels still should be validated in large prospective trials.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"6658794"},"PeriodicalIF":3.4,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Counseling Preferences Among Patients With Type 2 Diabetes: Implications for Personalized Care.","authors":"Thao Ngoc Phuong Nguyen, Chi Nguyen Thi, Trang Pham Thi Phuong, Quy Nguyen Ngoc, Hong Tham Pham","doi":"10.1155/jdr/9970845","DOIUrl":"10.1155/jdr/9970845","url":null,"abstract":"<p><p><b>Background:</b> In Vietnam, diabetes-related knowledge and self-management practices remain suboptimal, with limited interventions addressing the diverse counseling needs of Type 2 diabetes (T2D) patients. This study is aimed at identifying the counseling topics most preferred by T2D patients and examine the factors influencing their preferences to inform the development of targeted, cost-effective health counseling initiatives. <b>Methods:</b> A cross-sectional, descriptive study was conducted among 460 outpatients with T2D using structured interviews and medical records. Participants selected one of three counseling topics: disease-related knowledge (which provided information on the causes, symptoms, complications, and treatment options for T2D), nutrition and lifestyle (which included personalized guidance on food choices, healthy eating patterns, physical activity, and weight management), or medication information (which provided education on prescribed medications, dosage, timing, potential side effects, and proper administration). Multinomial logistic regression was employed to identify sociodemographic and clinical factors associated with counseling preferences. <b>Results:</b> Among the participants, nutrition and lifestyle counseling was the most preferred topic (49%), followed by disease-related knowledge (33%), and medication information (18%). Factors influencing preferences included occupational status, and complications were significantly associated with a preference for disease-related knowledge (<i>p</i> = 0.021 and <i>p</i> = 0.029, respectively). Marital status and complications influenced the preference for nutrition and lifestyle counseling (<i>p</i> = 0.043 and <i>p</i> = 0.011, respectively). Medication regimen and achieving target fasting blood glucose levels predicted a preference for medication information counseling (<i>p</i> < 0.05 and <i>p</i> < 0.001, respectively). <b>Conclusion:</b> This study serves as a reference for developing tailored health counseling programs to the specific needs of T2D patients. Personalized counseling approaches, particularly focusing on nutrition, lifestyle, and medication management, are critical for optimizing patient care and improving self-management. This study demonstrates that personalized counseling approaches, particularly in nutrition, lifestyle, and medication management, are critical for optimizing patient care and improving self-management. Additionally, it provides valuable insights for healthcare providers, policymakers, researchers, and stakeholders in implementing individualized care for T2D by considering specific factors that influence intervention choices.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"9970845"},"PeriodicalIF":3.4,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased Serum Adipose Triglyceride Lipase Level Is Associated With Renal Function Impairment in Patients With Type 2 Diabetes.","authors":"Ying Wang, Tongtong Liu, Nan Li, Tingting Zhao, Xiai Wu, Yanmei Wang, Xi Dong, Hailing Zhao, Weijing Liu, Ping Li","doi":"10.1155/jdr/9987648","DOIUrl":"10.1155/jdr/9987648","url":null,"abstract":"<p><p><b>Background:</b> Diagnosing diabetic kidney disease (DKD) remains a significant challenge. Research has increasingly focused on kidney injury resulting from lipid metabolism disorders. Adipose triglyceride lipase (ATGL), a pivotal enzyme in lipolysis, is essential for maintaining lipid metabolism balance. The objective of this study was to assess whether serum ATGL could serve as an early biomarker for DKD. <b>Methods:</b> The study divided 236 participants into four groups: healthy controls (<i>n</i> = 59), Type 2 diabetes mellitus (T2DM) with albumin-to-creatinine ratio (ACR) < 30 mg/g (<i>n</i> = 80), microalbuminuria (L-DKD) with ACR 30-300 mg/g (<i>n</i> = 41), and macroalbuminuria (H-DKD) with ACR ≥ 300 mg/g (<i>n</i> = 56). Relevant clinical data were collected, and serum levels of ATGL, kidney injury molecule-1 (KIM-1), and tumor necrosis factor-1 (TNFR-1) were measured. Various statistical analyses, including Spearman's correlation test, receiver operating characteristic curve analysis, multivariate logistic regression, and restricted cubic spline (RCS), were employed to assess the relationship between serum ATGL levels and renal function impairment in DKD. <b>Results:</b> Serum ATGL levels were notably lower in the T2DM, L-DKD, and H-DKD groups compared to healthy controls. Positive correlations were found between serum ATGL levels and estimated glomerular filtration rates (eGFR), while negative correlations were observed with diabetes duration, hypertension history, hyperlipidemia, urine ACR (UACR), 24-h urine total protein (UTP), serum creatinine (SCr), blood urea nitrogen, uric acid, TNFR-1, and KIM-1/creatinine (KIM-1/Cr) levels (<i>p</i> < 0.05). The receiver operating characteristic curve analysis demonstrated that the diagnostic performance of ATGL, when combined with traditional clinical markers, can enhance sensitivity. When participants were grouped by serum ATGL quartiles, it was observed that higher ATGL levels corresponded with lower UACR, 24 h-UTP, SCr, and TNFR-1 levels and higher eGFR. The odds ratios for elevated UACR and 24 h-UTP decreased, and eGFR increased with higher ATGL quartiles. Both univariate and multivariate logistic regression analyses indicated that serum ATGL is a protective factor against DKD development, even after adjusting for potential confounders. RCS analysis indicated a nonlinear dose-response association between serum ATGL levels and renal function metrics, specifically UACR and eGFR, in patients with DKD. <b>Conclusion:</b> Serum ATGL levels are linked to reduced renal function in T2DM patients. A decline in ATGL levels corresponded with a nonlinear rise in UACR and a drop in eGFR, suggesting that serum ATGL may serve as a potential biomarker for DKD development.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"9987648"},"PeriodicalIF":3.4,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12313390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Public Health System Funding for isCGM Reduces Socioeconomic Disparities in Type 2 Diabetes Control: A Cohort Study.","authors":"Fernando Sebastian-Valles, Jessica Jimenez-Diaz, Carolina Sager-La Ganga, Jon Garai-Hierro, Alicia Justel Enriquez, Alejandra Santamaría Barrena, Jon Portu Gamazo, Luis Eduardo Lander-Lobariñas, María Sara Tapia-Sanchiz, María Ausín Carrera, Julia Martínez-Alfonso, Jose Alfonso Arranz-Martín, Miguel Antonio Sampedro-Núñez, Victor Navas-Moreno, Purificación Martinez-Icaya, Mónica Marazuela, Iñigo Hernando-Alday","doi":"10.1155/jdr/5588397","DOIUrl":"10.1155/jdr/5588397","url":null,"abstract":"<p><p><b>Objective:</b> The objective of this study is to assess whether the provision of free intermittently scanned continuous glucose monitoring (isCGM) systems can reduce socioeconomic disparities in glycemic control among individuals with Type 2 diabetes mellitus (T2D) treated with multiple daily insulin injections. <b>Methods:</b> This is a cohort study involving 402 T2D patients from three hospitals, all of whom initiated isCGM use as part of routine clinical practice. The isCGM systems were provided free of charge through public healthcare funding, with no out-of-pocket cost to the patients. Glycated hemoglobin (HbA1c) levels were recorded before and after at least 3 months of sensor use. Socioeconomic status (SES) was determined based on the average annual net income per person within the census tract for each patient. <b>Results:</b> Prior to the sensor placement, the mean HbA1c was 8.9% for patients in the lowest SES quartile and 8.2% for those in the highest quartile (<i>p</i> = 0.009). Following isCGM implementation, significant HbA1c reductions were observed across all SES groups, with decreases of 1.0% in the lowest quartile and 0.6% in the highest (<i>p</i> < 0.001). Postintervention differences in HbA1c between SES quartiles were not statistically significant (<i>p</i> = 0.509). <b>Conclusion:</b> Public funding of isCGM systems is associated with a significant improvement in glycemic control and contributes to the reduction of pre-existing socioeconomic disparities in healthcare among T2D patients treated with insulin.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"5588397"},"PeriodicalIF":3.4,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Costunolide Reduces DN Inflammatory Response and Renal Thrombosis by Inhibiting NET Formation.","authors":"Xiangjing Wang, Lina Zhang, Ke Huang, Chengli Lou, Yuanying Xia, Yijing Zhou","doi":"10.1155/jdr/1159325","DOIUrl":"10.1155/jdr/1159325","url":null,"abstract":"<p><p><b>Background:</b> Diabetic nephropathy (DN), a prevalent microvascular complication of diabetes, is characterized by chronic inflammation, oxidative stress, and renal thrombosis. This study is aimed at assessing the therapeutic effects of costunolide (COS) on DN and investigating its mechanism of action in reducing inflammation and platelet activation-mediated thrombosis by inhibiting the formation of neutrophil extracellular traps (NETs). <b>Methods:</b> A DN mouse model was established using a high-sugar, high-fat diet combined with streptozotocin (STZ) administration, followed by treatment with varying doses of COS. The efficacy of COS was assessed through renal function indicators, including 24-h urinary protein levels, serum creatinine, and blood urea nitrogen, alongside renal histopathological analyses using hematoxylin-eosin, Masson's trichrome, and periodic acid-Schiff staining. Transcriptomic analysis was performed to identify gene expression changes in renal tissues after COS treatment. Based on transcriptomic findings, the impact of COS on inflammatory and platelet activation-related markers (IL-1<i>β</i>, IL-6, TNF-<i>α</i>, CCL2, and CD41) was further evaluated. Additionally, the expression of NET formation-related factors (MPO, CitH3, IGTAM, PAD4, C3, and fibrinogen) was analyzed using immunofluorescence, western blot, and ELISA. To validate the in vivo findings, isolated neutrophils were treated with COS in vitro to assess its inhibitory effects on NET formation, including markers such as SYTOX Green, CitH3, ROS, and PAD4. <b>Results:</b> COS treatment significantly improved renal function and mitigated histopathological damage in DN mice. Transcriptomic analysis indicated that COS modulated pathways associated with inflammation and platelet activation, including the complement and coagulation cascades, biosynthesis of cofactors, cytokine-cytokine receptor interactions, NET formation, and NOD-like receptor signaling. COS markedly reduced the expression of inflammatory markers (IL-1<i>β</i>, IL-6, TNF-<i>α</i>, and CCL2) and the platelet activation marker CD41 in renal tissues. Moreover, COS decreased the expression of NET-related proteins, including MPO, CitH3, PAD4, IGTAM, C3, and fibrinogen, while lowering the CitH3/H3 ratio. In vitro, COS significantly inhibited PMA-induced NET formation in neutrophils, as evidenced by reduced SYTOX Green + CitH3⁺ expression and decreased levels of PAD4 and ROS. <b>Conclusion:</b> COS alleviates inflammation and platelet activation-mediated thrombosis in DN mice, potentially by inhibiting excessive NET formation. These findings highlight the therapeutic potential of COS in managing DN.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"1159325"},"PeriodicalIF":3.4,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between DNA Methylation of <i>MTHFR</i> and Diabetic Kidney Disease.","authors":"Guoxiong Deng, Ziyi Feng, Xiaomu Kong, Peng Gao, Yongwei Jiang, Yi Liu, Meimei Zhao, Liang Ma","doi":"10.1155/jdr/8096423","DOIUrl":"10.1155/jdr/8096423","url":null,"abstract":"<p><p><b>Objective:</b> The objective of this study is to explore the association between <i>MTHFR</i> DNA methylation and diabetic kidney disease (DKD). <b>Methods:</b> This study involved 120 healthy people, 200 diabetes mellitus (DM) patients, and 200 DKD patients who visited China-Japan Friendship Hospital from 2022 to 2023. We selected four CpG islands for the detection of <i>MTHFR</i> DNA methylation: three located in the promoter region and one in Exon 2. The methylation rate of the <i>MTHFR</i> gene was measured using an enzyme digestion method combined with quantitative PCR. Clinical and biochemical characteristics between the two groups were also collected. <b>Results:</b> The methylation rate of the three CpG islands in the promoter region showed no significant differences between the DM and DKD patients. However, a significant difference in the CpG island methylation rate of the <i>MTHFR</i> gene Exon 2 was observed (25.14% vs. 21.94%, <i>p</i> < 0.001). Logistic regression analysis indicated that the methylation rate of <i>MTHFR</i> Exon2 is negatively associated with the occurrence and progression of DKD (OR = 0.947, 95% CI [0.919, 0.977], <i>p</i> = 0.001), with adjustments for gender, age, BMI, smoking, drinking, CHO, and TG. Significant differences were observed in the methylation ratios in different HCY groups (24.51% vs. 21.99%, <i>p</i> = 0.031). Linear regression showed <i>MTHFR</i> Exon 2 methylation negatively correlated with homocysteine (HCY) levels (<i>p</i> = 0.007). <b>Conclusion:</b> Methylation of the <i>MTHFR</i> gene Exon 2 is a protective factor for DKD and may contribute to its onset and progression through its influence on HCY levels. These findings highlight the potential of <i>MTHFR</i> methylation as a biomarker for DKD.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"8096423"},"PeriodicalIF":3.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between Blood Glucose Variability Indices Using Continuous Glucose Monitoring in Gestational Diabetes Patients and Abnormal Glucose Levels 42 Days Postpartum.","authors":"Rui Wang, Yuping Zhang, Huiqian Zeng, Jinyan Xiao, Mingming Qi, Lei Bao, Ruifen Jiao, Jing Liu, Yichun Li, Shuli He, Yunlong Li, Rui Li, Fan Ping, Yanping Liu","doi":"10.1155/jdr/1021066","DOIUrl":"10.1155/jdr/1021066","url":null,"abstract":"<p><p><b>Objective:</b> This study was aimed at analyzing the impact of blood glucose variability (GV) in gestational diabetes mellitus (GDM) patients on glucose outcomes 42 days postpartum and pregnancy outcomes. Additionally, it explored differences between various GV indices and evaluated their predictive values. <b>Methods:</b> This retrospective study included 75 pregnant women diagnosed with GDM. Continuous glucose monitoring (CGM) was initiated postdiagnosis, and outcomes were followed up. Oral glucose tolerance tests (OGTTs) were conducted 42 days postpartum to assess glucose response. <b>Results:</b> A total of 75 patients were included, among whom 8 (10.67%) exhibited impaired fasting glucose (IFG) and 7 (9.33%) impaired glucose tolerance (IGT) in the 42-day postpartum OGTT. No cases of diabetes were diagnosed. The results of the postpartum OGTT were significantly correlated with various GV indexes. In multivariate analysis, LBGI (OR: 1.437; 95% CI: 1.015-2.035; <i>p</i> = 0.041), <i>M</i> value (OR: 1.215; 95% CI: 1.030-1.434; <i>p</i> = 0.021), and TBR% (OR: 1.138; 95% CI: 1.020-1.271; <i>p</i> = 0.021) independently influenced IFG. Receiver operating characteristic (ROC) analysis indicated areas under the curve (AUCs) of 0.877 (95% CI: 0.760~0.994), 0.853 (95% CI: 0.730~0.975), 0.869 (95% CI: 0.748~0.991), and 0.793 (95% CI: 0.622~0.963) of IFG prediction model performance of TBR%, LBGI, <i>M</i> value, and HbA1c% combined with age, BMI, and family history of diabetes, respectively. <b>Conclusion:</b> Blood GV is an independent factor influencing IFG 42 days postpartum in GDM women, especially with hypoglycemia. It can increase the predictive efficiency of the postpartum abnormal blood glucose prediction model. <b>Trial Registration:</b> Chinese Clinical Trial Registry number: ChiCTR2100054833.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"1021066"},"PeriodicalIF":3.6,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12279430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peer Mentoring Improves Diabetes Technology Use and Reduces Diabetes Distress Among Underserved Communities: Outcomes of a Pilot Diabetes Support Coach Intervention.","authors":"Jennifer Maizel, Michael J Haller, David M Maahs, Ananta Addala, Stephanie L Filipp, Rayhan A Lal, Matthew J Gurka, Lauren Figg, Melanie Hechavarria, Dessi P Zaharieva, Keilecia G Malden, Sarah Westen, Brittney N Dixon, Korey Hood, Eleni Sheehan, Jessie J Wong, William T Donahoo, Marina Basina, Angelina Bernier, Eliana Frank, Ashby F Walker","doi":"10.1155/jdr/1970247","DOIUrl":"10.1155/jdr/1970247","url":null,"abstract":"<p><p><b>Background:</b> There are well-documented disparities in diabetes care outcomes and technology usage, stemming from differences in healthcare access, distrust in healthcare providers, and other factors. This study evaluated patient-level outcomes of a diabetes support coach (DSC) intervention aimed at improving underserved adults' diabetes technology use, diabetes distress, and HbA1c levels. <b>Methods:</b> As part of a Project Extension for Community Healthcare Outcomes (ECHO) Diabetes program, a social support intervention involving 28 DSCs was piloted at 33 Federally Qualified Health Centers (FQHCs) in Florida and California from May 2021 to May 2022. DSCs, who were adults with diabetes, served in a capacity similar to peer mentors and community health workers and received uniform training/oversight by a clinical team. Intervention participants (<i>n</i> = 74 adults with insulin-requiring diabetes at FQHCs) self-enrolled and engaged with DSCs via text messages, phone calls, and events. Participants' outcomes were evaluated cross-sectionally via the Diabetes Distress Scale (DDS-17) and a diabetes technology usage survey and longitudinally via HbA1c tests upon enrollment and at 6-month follow-up. A group of adults with insulin-requiring diabetes from the same FQHCs who did not receive the DSC intervention (<i>n</i> = 363) was used for comparison. Descriptive statistics were computed for all outcomes (<i>n</i>, percentage; mean, SD/95% CI). Between-group comparisons were evaluated via chi-squared and <i>t</i>-tests. <b>Results:</b> DSC intervention participants reported significantly lower diabetes distress than the comparison group (DDS-17 score mean = 1.6 vs. 2.1, <i>p</i> < 0.001), and significantly more participants in the DSC intervention regularly used continuous glucose monitors (CGMs) than the comparison group (69.9% vs. 38.8%, <i>p</i> < 0.0001). There were no significant differences in insulin pump usage or HbA1c. <b>Conclusions:</b> Lower diabetes distress and greater CGM usage among intervention participants suggest that the DSCs' shared lived experiences and healthcare navigation support positively influenced underserved adults' outcomes. These findings show DSCs' potential for improving diabetes care and technology equity.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2025 ","pages":"1970247"},"PeriodicalIF":3.6,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}